Polyglutamic acid compositions and methods of use

By penetrating the vaginal epithelium with different polymer chain lengths, the side effects and risks of vaginal drying treatment methods in the prior art are solved, and rapid and long-lasting symptom relief and vaginal humidity maintenance are achieved. Treatment of menopause-related symptoms.

CN118922195APending Publication Date: 2024-11-08BONAFIDE HEALTH LLC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380024964.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-03-02
Filing Date
2023-03-02
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Existing treatments for vaginal dryness have side effects and risks, especially estrogen therapy and hyaluronic acid therapy, and there is a lack of effective alternatives for patients who are reluctant or unable to receive these therapies.

Method used

Develop a composition of one or more polyglutamic acid compounds with pharmaceutically acceptable carriers to penetrate into different layers of vaginal epithelial tissue through the proportion of polyglutamic acid compounds of different polymer chain lengths, providing lubricating and repairing effects, Used to treat and relieve symptoms of vaginal dryness.

Benefits of technology

The composition can quickly and last longer relieve symptoms of vaginal dryness, relieve menopause-related symptoms, and maintain healthy humidity levels in vaginal tissues, avoid intercourse pain, and have good stability and safety.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005022422850000011
    Figure BDA0005022422850000011
  • Figure BDA0005022422850000071
    Figure BDA0005022422850000071
  • Figure BDA0005022422850000091
    Figure BDA0005022422850000091
Patent Text Reader

Abstract

Compositions comprising one or more polyglutamic acid compounds are disclosed. The composition is used for treating, relieving, preventing or reducing vaginal dryness symptoms and symptoms related to climacteric. The invention also discloses a suppository preparation of the composition.
Need to check novelty before this filing date? Find Prior Art

Description

Background Art

[0001] Vaginal dryness is a common condition that affects women of all ages. However, vaginal dryness is most common in postmenopausal women. Vaginal dryness in postmenopausal women may be related to decreased estrogen levels. Topical estrogen therapy has been the most common treatment for vaginal dryness, but this therapy carries risks such as vaginal bleeding and increased risk of uterine cancer. For patients who are unwilling or unable to consider estrogen therapy, hyaluronic acid is an alternative therapy. However, it also has side effects, including vulvovaginal candidiasis and bacterial vaginosis. Therefore, the methods and compositions for treating vaginal dryness in the prior art are insufficient, and this article provides a solution to help relieve vaginal dryness. Summary of the invention

[0002] Embodiments of the present disclosure are directed to novel compositions containing one or more polyglutamic acid compounds and their use in treating and / or alleviating symptoms of vaginal dryness and symptoms associated with menopause.

[0003] These and other features, aspects and advantages of the present embodiments will be understood with reference to the following description and appended claims. DETAILED DESCRIPTION

[0004] Compositions comprising one or more polyglutamic acid compounds and a pharmaceutically acceptable carrier are described herein. Each polyglutamic acid compound can be prepared by reacting a glutamate monomer with a suitable initiator. The molecular weight of each polyglutamic acid compound is determined by the number of glutamic acid monomers that have been connected, which number corresponds to the n value described below.

[0005] The structure of polyglutamic acid compound is shown below:

[0006]

[0007] n refers to the chain length of the polyglutamic acid compound, which may be 300 to 30,000. The molecular weight of the polyglutamic acid compound disclosed herein may be about 50 to 4,000 kDa. The composition described herein may contain one or more polyglutamic acid compounds that may have different polymer chain lengths (ie, different n values).

[0008] For example, but not limited to, the composition may include: a first polyglutamate compound, wherein the n value of the first polyglutamate compound is about 300 to 500; a second polyglutamate compound, wherein the n value of the second polyglutamate compound is about 1,000 to 10,000; and a third polyglutamate compound, wherein the n value of the third polyglutamate compound is about 20,000 to 30,000.

[0009] The number of polyglutamic acid compounds with different n values ​​in the composition is not particularly limited. In some embodiments, the composition may include one, two, three, four, five, six or more different polyglutamic acid compounds with different n values.

[0010] Without being bound by any particular theory, the compositions of the present disclosure containing one or more polyglutamic acid compounds produce unexpectedly excellent effects because these compounds are able to penetrate into different layers of vaginal epithelial tissue according to the specific ratio of polyglutamic acid compounds having different n values. For example, the composition may include a first polyglutamic acid compound and a second polyglutamic acid compound, wherein the n value of the first polyglutamic acid compound is less than the n value of the second polyglutamic acid compound. It is believed that polyglutamic acid compounds with smaller n values ​​are able to penetrate deeper layers of vaginal epithelial cells than polyglutamic acid compounds with larger n values. And it is further believed that the second polyglutamic acid compound having an n value greater than the first polyglutamic acid compound will not penetrate into the deeper epithelial layer, but rather, the second polyglutamic acid compound will be closer to the surface than the first polyglutamic acid compound.

[0011] Certain embodiments include a first polyglutamic acid compound, a second polyglutamic acid compound, and a third polyglutamic acid compound. In certain embodiments, the first polyglutamic acid compound is a polyglutamic acid compound comprising a greater number of glutamic acid monomers than the second polyglutamic acid compound. The second polyglutamic acid compound comprises a greater number of glutamic acid monomers than the third polyglutamic acid compound. In certain embodiments, the first polyglutamic acid compound is configured to penetrate into the stratum corneum of the subject's vaginal wall, the second polyglutamic acid compound is configured to penetrate into the stratum granulosum of the subject's vaginal wall, and the third polyglutamic acid compound is configured to penetrate into the stratum spinosum of the subject's vaginal wall. In some embodiments, one or more polyglutamic acid compounds may have a sufficiently large n value so that it does not penetrate any skin layer, but stays on the skin surface, and may act as a lubricant.

[0012] The amount of each polyglutamic acid compound in any composition described herein is not particularly limited and can be from about 10 μg to about 10 g. For example, the amount can be 10 μg, 15 μg, 20 μg, 25 μg, 30 μg, 35 μg, 40 μg, 45 μg, 50 μg, 55 μg, 60 μg, 65 μg, 70 μg, 75 μg, 80 μg, 85 μg, 90 μg, 95 μg, 100 μg, 125 μg, 150 μg, 175 μg, 200 μg, 225 μg, 250 μg, 275 μg, 300 μg, 325 μg, 350 μg, 375 μg, 400 μg, 425 μg, 450 μg, 475 μg, 500 μg, 525 μg, 575 μg, 580 μg, 590 μg, 600 μg, 610 μg, 625 μg, 630 μg, 640 μg, 650 μg, 660 μg, 670 μg, 680 μg, 690 μg, 700 μg, 75 ... 5μg, 600μg, 625μg, 650μg, 675μg, 700μg, 725μg, 750μg, 775μg, 800μg, 825μg, 850μg, 875μg, 900μg, 925μg, 950μg, 975μg, 1000μ g, 5mg, 10mg, 15mg, 20mg, 25mg, 30mg, 35mg, 40mg, 45mg, 50mg, 55mg, 60mg, 65mg, 70mg, 75mg, 80mg, 85mg, 90mg, 95mg, 100mg, 125 mg, 150mg, 175mg, 200mg, 225mg, 250mg, 275mg, 300mg, 325mg, 350mg, 375mg, 400mg, 425mg, 450mg, 475mg, 500mg, 525mg, 575mg , 600mg, 625mg, 650mg, 675mg, 700mg, 725mg, 750mg, 775mg, 800mg, 825mg, 850mg, 875mg, 900mg, 925mg, 950mg, 975mg, 1000mg, 1 g, 8.0 g, 8.25 g, 8.5 g, 8.75 g, 9.0 g, 8.25 g, 9.5 g, 9.75 g, 10 g or any amount therebetween.

[0013] Compositions disclosed herein can be used to treat, prevent or alleviate vaginal dryness, vaginal itching and / or vaginal burning (burning). In some embodiments, compositions described herein can be used to maintain healthy vaginal moisture levels. In some embodiments, compositions described herein can be used to accelerate wound healing speed, prevent urinary tract infections and / or maintain the pH value of vaginal tissue. In certain embodiments, compositions described herein are applied to a subject to avoid sexual intercourse pain. In certain embodiments, compositions described herein are applied to a subject to rejuvenate vaginal tissue.

[0014] In certain embodiments, the composition can be applied to the vaginal tissue of the subject to treat, prevent, alleviate and / or alleviate vaginal dryness symptoms. In certain embodiments, the composition can be applied to the vaginal tissue of the subject to maintain healthy vaginal moisture levels. In certain embodiments, the composition can be applied to the vaginal tissue of the subject to treat, prevent and / or alleviate vaginal dryness symptoms caused by menopause. In some embodiments, the composition can be applied to the vaginal tissue of the subject to treat, prevent and / or alleviate one or more menopausal symptoms. In certain embodiments, the composition can be applied to the vaginal tissue of the subject to alleviate the pain associated with sexual activity (including sexual intercourse). In certain embodiments, the composition can be applied to the vaginal tissue of the subject to treat, prevent and / or alleviate vaginal itching. In certain embodiments, the composition can be applied to the vaginal tissue of the subject to treat, prevent and / or alleviate vaginal burning. In certain embodiments, the composition can be used for one or more of the aforementioned situations.

[0015] In some embodiments, the compositions disclosed herein are in the form of pharmaceutically effective salts. The phrase "pharmaceutically acceptable salt" is recognized in the art, and as used herein, includes but is not limited to salts of acidic or basic groups that may be present in the compositions disclosed herein. Essentially alkaline compounds can form various salts with various inorganic acids and organic acids. The acid that can be used to prepare the pharmaceutically acceptable acid addition salts of such basic compounds is those acids that form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, including but not limited to sulfates, citrates, maleates, acetates, oxalates, hydrochlorides, hydrobromides, hydroiodates, nitrates, sulfates, bisulfates, phosphates, acid phosphates, isonicotinates, acetates, lactates, salicylates, citrates, acid citrates, tartrates, oleates, tannates, pantothenates, bitartrates, ascorbates, succinates, maleates, gentisates, fumarates, gluconates, glycerates, glucuronates (gl The compounds present in the compositions disclosed herein that contain an amino moiety may form pharmaceutically acceptable salts with various amino acids in addition to the acids mentioned above. The compounds present in the compositions disclosed herein that are acidic in nature are capable of forming basic salts with various pharmaceutically acceptable cations. Non-limiting examples of such salts include alkali or alkaline earth metal salts, particularly calcium, magnesium, sodium, lithium, zinc, potassium, silicon, phosphorus and iron salts.

[0016] The phrase "pharmaceutically acceptable carrier" is recognized in the art and includes pharmaceutically acceptable materials, compositions or vehicles suitable for administering the compounds of the invention to mammals. Carriers include liquid or solid fillers, diluents, excipients, solvents or encapsulating materials used to carry or transport the target agent from one organ or body part to another organ or body part.

[0017] Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient. Some examples of materials that can be used as pharmaceutically acceptable carriers include: sugars such as lactose, glucose, and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethylcellulose, ethylcellulose, and cellulose acetate; tragacanth powder; malt; gelatin; talc; excipients such as cocoa butter and wax for suppositories; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil; glycols such as propylene glycol; polyols such as glycerol, glycerides, sorbitol, mannitol, and polyethylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffers such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethanol; phosphate buffered saline; and other nontoxic compatible substances used in pharmaceutical formulations. In one embodiment, the pharmaceutically acceptable carrier is suitable for intravenous administration. In another embodiment, the pharmaceutically acceptable carrier is suitable for local injection.

[0018] The term "pharmaceutically acceptable ester" refers to a relatively nontoxic esterification product of a compound of the invention. These esters can be prepared in situ during the final separation and purification of the compound, or by reacting the purified compound in free acid form or a hydroxyl with a suitable esterifying agent alone. Carboxylic acids can be converted into esters by treatment with an alcohol in the presence of a catalyst. Hydroxyl compounds can be converted into esters by treatment with an esterifying agent such as an alkanoyl halide. The term also includes lower hydrocarbon groups that can be solvated under physiological conditions, such as alkyl esters, methyl esters, ethyl esters, and propyl esters.

[0019] The dosage form of the compositions described herein is not particularly limited. In certain embodiments, the compositions are formulated into topical dosage forms, such as creams or ointments. In certain embodiments, the compositions are formulated into gels. In certain embodiments, the compositions are formulated into suppositories.

[0020] In certain embodiments, the suppository formulation comprises one or two polyglutamic acid compounds, a solubilizing agent, a humectant, a surfactant and / or one or more suppository bases. The suppository formulation may also include an emollient. An example of a solubilizing agent is water. An example of a humectant is glycerol. An example of a surfactant is polysorbate 80. Examples of suppository bases include PEG4000, Gelucire43 / 01, PEG3350, witepsol and C 12 -C 18Saturated fatty acid glyceride. An example of an emollient is softisan 378. The molecular weight of the one or two polyglutamic acid compounds is 50 kDa to 2000 kDa. For example, the molecular weight of the polyglutamic acid compound can be 50 kDa, 100 kDa, 150 kDa, 200 kDa, 250 kDa, 300 kDa, 350 kDa, 400 kDa, 450 kDa, 500 kDa, 550 kDa, 600 kDa, 650 kDa, 700 kDa, 750 kDa, 800 kDa, 850 kDa, 900 kDa, 950 kDa, 1000 kDa, 1 kDa, 1900 kDa, 1950 kDa or 2000 kDa. The weight percentage (% w / w) of each polyglutamic acid compound in any composition described herein is not particularly limited and can be from about 0.01% to about 1%.For example, it can be 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.10%, 0.11%, 0.12%, 0.13%, 0.14%, 0.15%, 0.16%, 0.17%, 0.18%, 0.19%, 0.20%, 0.21%, 0.22%, 0.23%, 0.24%, 0.25 %, 0.26%, 0.27%, 0.28%, 0.29%, 0.30%, 0.31%, 0.32%, 0.33%, 0.34%, 0.35%, 0.36%, 0.37%, 0.38%, 0.39%, 0.40%, 0.41%, 0.42%, 0.43%, 0.44%, 0.45%, 0.46%, 0.47%, 0.48%, 0.49%, 0.50%, 0. 51%, 0.52%, 0.53%, 0.54%, 0.55%, 0.56%, 0.57%, 0.58%, 0.59%, 0.60%, 0.61%, 0.62%, 0.63%, 0.64%, 0.65%, 0.66%, 0.67%, 0.68%, 0.69%, 0.70%, 0.71%, 0.72%, 0.73%, 0.74%, 0.75%, 0.76%, %. 0.77%, 0.78%, 0.79%, 0.80%, 0.81%, 0.82%, 0.83%, 0.84%, 0.85%, 0.86%, 0.87%, 0.88%, 0.89%, 0.90%, 0.91%, 0.92%, 0.93%, 0.94%, 0.95%, 0.96%, 0.97%, 0.98%, 0.99%, 1% or more, or any value therebetween. The weight percentage (% w / w) of the solubilizer, humectant, surfactant, the one or more suppository bases and emollients in the suppository preparation is also not particularly limited, and can be 1% to 100%, about 0.1% to 11.4%, 0.1% to 1.4%, 0% to 100%, and 0% to 100%, respectively. The amount of polyglutamic acid compound, solubilizer, moisturizer, surfactant, suppository base and / or emollient is a synergistic ratio. As used herein, "synergistic ratio" refers to a ratio that produces unexpectedly excellent pharmacological and physiological effects in a subject. An example of a synergistic ratio of the amount of polyglutamic acid compound: the amount of solubilizer: the amount of moisturizer: the amount of surfactant: the amount of suppository base is 5:396:50:28:1521.

[0021] In certain embodiments, the suppository formulation comprises only one polyglutamic acid compound. In certain embodiments, the molecular weight of the compound is 100 kDa, 700 kDa or 2000 kDa. In certain embodiments, the suppository formulation comprises a solubilizer, a humectant, a surfactant and a suppository base. In certain embodiments, the solubilizer is water, the humectant is glycerol, the surfactant is polysorbate 80, and the suppository base is C 12 -C 18 Saturated fatty acid glycerides.

[0022] In certain embodiments, the suppository formulation comprises two polyglutamic acid compounds. In certain embodiments, the molecular weight of the compounds is 100 kDa and 700 kDa.

[0023] In certain embodiments, the suppository formulation can disintegrate in 5-10 minutes, 10-20 minutes, or 20-30 minutes. In certain embodiments, the suppository formulation can be applied once every two days, every three days, every four days, every five days, every six days, every seven days, every eight days, every nine days, every ten days, every two weeks, every month, or longer to quickly and lastingly relieve vaginal dryness symptoms and symptoms associated with menopause.

[0024] Although the present invention has been described in some detail for purposes of clarity and understanding, it will be understood that various changes in form and details may be made without departing from the true scope of the invention.

[0025] Example

[0026] Example 1

[0027] In one embodiment, polyglutamic acid (Mw: 100 kDa; 5 mg; 0.25% w / w) was mixed with water (396 mg; 19.8% w / w), glycerol (50 mg; 2.5% w / w), polysorbate 80 (28 mg; 1.4% w / w) and C 12 -C 18 Saturated fatty acid glycerides (1521 mg; 76.04% w / w) were mixed to obtain a white suppository. The suppository was subjected to a dissolution study using a phosphate buffer having a pH range of about 4.2-4.5, which is within the normal vaginal pH range (3.8-5.0). The percentage of polyglutamic acid in the buffer was determined at 0.5 hour, 0.75 hour, 1 hour, 2 hours, 3 hours, 6 hours, 24 hours, 30 hours, and 48 hours, and the dissolution data are shown in Table 1 below.

[0028] Table 1: Dissolution data

[0029]

[0030] The suppository was observed to completely disintegrate within 30 minutes. The data showed that 67% of the polyglutamic acid compound dissolved within 30 minutes, and the polyglutamic acid compound was completely dissolved in the buffer at 3 hours. Unexpectedly, stable dissolution was observed from 0.5 hours to 3 hours. Also unexpectedly, 100% of the polyglutamic acid compound remained in the buffer at 48 hours, indicating that the compound is stable in the vaginal tissue and can therefore moisturize the vaginal tissue for more than 2 days once applied. These unexpected results indicate that the composition can quickly and durably relieve the symptoms of vaginal dryness.

[0031] Example 2

[0032] The vaginal suppository composition described in Example 1 above was studied to evaluate its short-term stability compared to the placebo prototype composition. The placebo composition is the same as the vaginal suppository composition, except that the former does not contain any polyglutamic acid compound. Both compositions will be placed in the ICH stability test for 3 months at 2-8°C and 25°C / relative humidity 60%. At the end of the 1st and 2nd month, the stability of the vaginal suppository composition will be evaluated by visual observation of the appearance and the amount of polyglutamic acid compound remaining in the composition. At the end of the 3rd month, in addition to visual observation of the appearance and the amount of polyglutamic acid remaining in the composition, the stability of the vaginal suppository composition will also be evaluated by the amount of dissolved polyglutamic acid compound. As for the placebo composition, its stability will be evaluated by visual observation of appearance and placebo interference at the end of each month.

[0033] Example 3

[0034] A test will be conducted in which the activity and efficacy of polyglutamic acid compounds of different polymer lengths are tested using an in vitro vaginal tissue test device. Different polyglutamic acid compounds (i.e., having different n values) are applied to the test device, and the ability of these compounds to penetrate into the various tissue layers of the vaginal wall is related to their n value (i.e., the number of monomers in the polyglutamic acid compound) and the relative effect on vaginal moisture. In addition, compositions of polyglutamic acid compounds with different polymer chain lengths (i.e., different n values) at different concentrations will be tested to determine the effect on vaginal moisture and penetration of vaginal tissue layers.

[0035] Example 4

[0036] Certain compositions described herein will be tested for their effects on the vaginal epithelium in a postmenopausal rat model.

[0037] 30 female Wistar / Sprague rats (8 weeks old) were purchased from the Firat University Laboratory Animal Center. All rats were housed individually in a clean environment with controlled temperature, humidity and illumination (12-hour light-dark cycle) and free access to standard commercial diets and water. All experimental procedures followed the guidelines determined by the Use of Laboratory Animals and were approved by the Animal Care and Use Committee of Firat University.

[0038] Rats with a regular estrous cycle of 4 days were selected for the experiment. Rats were divided into 7 groups as shown in Table 2. After an adaptation period, rats were subjected to ovariectomy (OVX) or sham surgery (control) under anesthesia. Adipose tissue of equal weight was taken out from the rats in the control group. After the operation, vaginal smears were evaluated every day. Only rats with a regular estrous cycle of 4 days (before and after sham surgery / OVX) and rats with constant leukocytes (after OVX) were used for vaginal smears (10 rats per group). The remaining rats were given placebo (vehicle) gel by intravaginal or oral administration, and the dosage was the same as the dosage of the composition received by the rats. The rat body weight was measured weekly.

[0039] Table 2. Study groups

[0040]

[0041] *Product doses were calculated using allometric scaling, which takes into account differences in body surface area to calculate the rat equivalent dose using the following calculation, assuming a human body weight of 60 kg: RD = HED (g) / 60 kg * 6.17 (e.g. (50 mg / 60) * 6.17 = 5.14 mg / kg BW; where RD is the rat dose of the product, HED is the human equivalent dose of the product, and 6.17 is the conversion factor for converting the human dose to the rat dose.

[0042] On day 15, the therapeutic effect of each composition on vaginal atrophy was determined by histological examination of vaginal tissue obtained from each rat. Vaginal smears were fixed and tested, and the expression of leukocyte esterase, β-glucuronidase and coagulase was used to determine the effect of each composition on the vaginal microecological system. All rats were then killed by cervical dislocation, and their vaginas and uteri were removed. After carefully removing any adhering tissue, the wet weight of each uterus was determined. In order to minimize the differences caused by dissection, all uteri were dissected at the same distance above the cervix. Vaginal tissue was then removed and cut into 1mm×1mm×2mm slices and stained with 2.5% glutaraldehyde. Some vaginal samples were taken and processed by standard procedures for histological examination (4-5μm slices stained with hematoxylin and eosin).

[0043] The repair ability of each composition was detected by Western blotting. Vaginal VEGF, p-AKT, COX-2, ERα and ERβ were detected by Western blotting. In the Western blotting method, the proteins were separated in a 10% polyacrylamide gel, electrotransferred to a polyvinylidene fluoride membrane, and the strips were blocked in 5% milk powder for 1 hour at room temperature and cultured with different primary antibodies (1:1000). The culture was carried out in PBS supplemented with 5% skim milk powder. After washing with Tris buffered saline (TBS) (TBS-T) containing 0.1% Tween-20, the membrane was cultured with an anti-rabbit IgG antibody conjugated with horseradish peroxidase for 1 hour at room temperature. After washing with TBS-T, the antigen-antibody complex was visualized by using an enhanced chemiluminescence detection kit.

Claims

1. A composition for treating vaginal dryness, comprising one or more polyglutamic acid compounds and a pharmaceutically acceptable carrier. 2 . The composition of claim 1 , wherein the one or more polyglutamate compounds comprises a first polyglutamate compound and a second polyglutamate compound.

3. The composition according to claim 2, further comprising a third polyglutamate compound.

4. The composition of claim 2, wherein the first polyglutamate compound has a value of n that is less than the value of n of the second polyglutamate compound, wherein the value of n is the number of glutamic acid monomers linked together to form each polyglutamate compound.

5. The composition of claim 3, wherein the n value of the first polyglutamate compound is less than the n value of the second polyglutamate compound, and the n value of the third polyglutamate compound is greater than the n value of the second polyglutamate compound, wherein the n value is the number of glutamic acid monomers linked together to form each polyglutamate compound.

6. The composition according to claim 1, wherein the composition is in the form of a suppository.

7. The composition according to claim 1, wherein the composition is in the form of a cream.

8. The composition according to claim 6, wherein the suppository formulation comprises one or two polyglutamic acid compounds.

9. The composition according to claim 8, further comprising a solubilizer, a humectant, a surfactant and one or more suppository bases.

10. The composition according to claim 9, wherein the amounts of the polyglutamic acid compound, the solubilizer, the humectant, the surfactant and the suppository base are in a synergistic ratio.

11. The composition of claim 8, wherein the composition comprises a polyglutamic acid compound.

12. The composition according to claim 11, wherein the molecular weight of the polyglutamic acid compound is 100 kDa.

13. The composition according to claim 12, further comprising a solubilizer, a humectant, a surfactant and a suppository base.

14. The composition of claim 13, wherein the solubilizer is water, the humectant is glycerin, the surfactant is polysorbate 80, and the suppository base is C 12 -C 18 Saturated fatty acid glycerides.

15. The composition of claim 4, wherein the molecular weight of the first polyglutamate compound is 100 kDa, and the molecular weight of the second polyglutamate compound is 700 kDa.

16. The composition according to claim 15, wherein the composition is in the form of a suppository.

17. The composition according to claim 16, further comprising a solubilizer, a humectant, a surfactant and a suppository base.

18. The composition of claim 17, wherein the solubilizer is water, the humectant is glycerin, the surfactant is polysorbate 80, and the suppository base is C 12 -C 18 Saturated fatty acid glycerides.

19. A method of treating vaginal dryness comprising applying the composition of claim 1 to the vaginal cavity of a subject.

20. The method of claim 19, wherein the composition is in the form of a suppository.

21. The method of claim 20, wherein the suppository formulation comprises only one polyglutamate compound.

22. The method of claim 20, wherein the suppository formulation comprises a first polyglutamate compound and a second polyglutamate compound.

23. A method of maintaining healthy vaginal moisture levels comprising applying the composition of claim 1 to vaginal tissue of a subject.

24. A method for treating, preventing and / or alleviating one or more menopausal symptoms, comprising applying the composition according to claim 1 to vaginal tissue of a subject.

25. The method of claim 24, wherein the symptom is vaginal dryness, vaginal itching, vaginal burning and / or pain associated with sexual activity.

26. The method of claim 25, wherein the pain is caused by sexual intercourse.